What Are The Recommended Parameters And Clinical Techniques For Operating A Transcutaneous 1064 Nm Nd:yag Laser When Treating Large Proliferate Keloids? Expert Protocol For Safe And Effective Treatment

For large proliferative or fibrotic keloids, a transcutaneous 1064 nm Nd:YAG laser is generally operated at 35–50 W in continuous-wave or chopped mode, with continuous epidermal cooling and conservative endpoint assessment. Lower power is appropriate for more erythematous lesions because their vascular content can increase thermal absorption. Treatment is typically performed over 3–5 sessions spaced 6–8 weeks apart, but exact settings must be individualized by an experienced laser clinician using the specific device manufacturer’s protocol.

The objective is controlled reduction of deep keloid vascularity and fibroblast activity without causing surface blanching, coagulation points, or necrosis. Prolonged reperfusion time, rather than visible tissue whitening or charring, is the preferred clinical endpoint.

How to Select the Treatment Parameters

Power for Large or Fibrotic Keloids

The reference range is 35–50 W delivered in continuous-wave or chopped mode. This range should be treated as a starting framework rather than a universal prescription, because tissue thickness, vascularity, lesion color, skin phototype, and device design affect heat deposition.

More erythematous keloids generally warrant the lower end of the power range. Increased hemoglobin content can produce greater absorption and a faster temperature rise than in pale, dense, fibrotic tissue.

Continuous-Wave Versus Chopped Delivery

Continuous-wave delivery provides sustained heating and therefore requires careful movement, cooling, and endpoint monitoring. Chopped delivery can reduce uninterrupted heat accumulation while still allowing treatment of deeper tissue.

The selected mode should be consistent with the laser’s validated operating protocol. The operator should avoid prolonged stationary delivery in any single area, particularly when treating thick or irregular lesions.

Cooling During Laser Delivery

Continuous surface cooling is essential. Clear ice without air inclusions may be used when compatible with the handpiece and treatment method, because it can cool the epidermis while allowing transmission of the 1064 nm wavelength.

Cooling should be maintained throughout energy delivery rather than applied only after treatment. It helps limit epidermal injury and reduces the risk of excessive superficial heating.

Clinical Technique and Endpoint

Treat the Lesion Methodically

Large keloids should be divided into manageable treatment zones so that exposure, cooling, and tissue response can be monitored consistently. The handpiece should be moved systematically across the lesion, with attention to thickness and color differences between zones.

The operator should avoid concentrating energy at lesion edges, sharply raised areas, or irregular vascular regions unless the device protocol specifically supports such targeting. These areas can develop uneven thermal exposure.

Avoid Blanching and Coagulation Points

Visible tissue blanching, white coagulation points, charring, or sharply demarcated thermal injury indicate excessive local heating. These findings should not be pursued as treatment goals.

Excessive thermal injury can cause tissue necrosis, delayed healing, and a greater risk of scar recurrence. A non-ablative treatment should remain controlled and should not be converted into an ablative injury through excessive dwell time or overlapping passes.

Use Reperfusion as the Endpoint

The preferred endpoint is prolonged reperfusion time in the irradiated tissue. After cooling or temporary compression is released, the treated area should be observed for delayed return of color rather than judged by immediate whitening.

This endpoint is consistent with reducing perfusion in the keloid while avoiding overt coagulation. The clinician should document the response and use it to guide subsequent sessions.

Adjust for Lesion Color and Density

Paler, denser, more fibrotic lesions may require treatment toward the higher part of the stated power range, while redder lesions usually require more conservative settings. This adjustment should be made alongside assessment of thickness, prior treatment, skin type, and thermal response.

Color alone is insufficient to determine treatment parameters. A thick, pale lesion may still retain substantial deep vascularity, while a red lesion may heat rapidly despite appearing superficially modest.

Why the 1064 nm Wavelength Is Used

Deep Vascular Targeting

The 1064 nm wavelength penetrates deeply into the dermis and can reach vessels within the deeper portion of a keloid. Selective damage to these vessels may reduce the lesion’s blood supply and create a less favorable environment for continued fibroblast activity and collagen production.

The treatment is therefore directed at the deep vascular component, not merely the visible surface redness.

Effects on Fibrotic Tissue

By reducing perfusion and influencing fibroblast activity, the laser may help decrease keloid volume over a course of treatments. Dense collagen itself is not necessarily destroyed uniformly by the treatment; the clinical effect depends substantially on vascular targeting and controlled thermal remodeling.

Large keloids often require multiple sessions because a single treatment cannot safely deliver sufficient heat throughout a thick lesion without increasing the risk of necrosis.

Understanding the Trade-offs

More Power Does Not Mean Better Clearance

Increasing power may improve energy delivery to dense tissue, but it also increases the risk of excessive thermal accumulation. Necrosis and delayed wound healing can worsen scarring and potentially contribute to recurrence.

The correct endpoint is controlled hypoperfusion, not tissue destruction visible at the surface.

Vascular Laser Parameters Are Not Interchangeable

Pulse durations, spot sizes, fluences, and vessel endpoints described for telangiectasias or hemangiomas should not be transferred directly to large keloid treatment. Keloids are thicker, structurally irregular, and clinically managed with a different delivery objective.

In particular, vessel disappearance, darkening, purpura, or vessel rupture are not appropriate universal endpoints for transcutaneous keloid treatment.

Avoid Unvalidated Pulse Stacking

Long-pulsed Nd:YAG protocols for vascular disease commonly caution against pulse stacking because residual heat can accumulate and damage the dermis. The same thermal concern applies when treating thick keloids: overlapping exposures should be controlled according to the device protocol, lesion response, and cooling capacity.

Combination With CO2 Requires Specialist Planning

A CO2 laser may be combined with 1064 nm Nd:YAG treatment in selected protocols to address superficial and deep components of a lesion. However, this is a multimodal intervention with a higher cumulative injury burden and should not be assumed to improve outcomes in every patient.

If combination treatment is considered, the sequence, interval, energy settings, wound care, and recurrence-prevention strategy should come from a validated specialist protocol rather than being improvised.

Deep Penetration Has Safety Consequences

The 1064 nm wavelength can penetrate approximately several millimeters into tissue, which is useful for deep targets but increases the possibility of nonspecific thermal injury. Improper delivery can cause dermal necrosis, scarring, pigmentary change, or injury to nearby nerves and other structures.

Treatment near anatomically sensitive areas requires particular caution, and interstitial or transmucosal techniques should not be substituted for transcutaneous treatment without appropriate training and device-specific guidance.

Planning the Treatment Course

Session Interval

The reference protocol recommends 3–5 sessions at 6–8-week intervals. This interval allows the tissue response to develop and gives the clinician time to evaluate delayed inflammation, healing, flattening, and recurrence behavior.

Shortening the interval without a clear clinical rationale may expose incompletely recovered tissue to additional thermal stress.

Assess Before Each Session

Before repeating treatment, assess:

Lesion color, thickness, firmness, and vascularity
Healing from the previous session
Areas of ulceration, necrosis, infection, or persistent inflammation
Pain, tenderness, pruritus, and functional limitation
Skin phototype and risk of post-inflammatory pigment alteration
Previous intralesional, surgical, or laser treatments

The next session should be postponed or modified if the tissue has not healed adequately or if the prior endpoint suggested excessive injury.

Use a Recurrence-Prevention Strategy

Laser treatment alone may not address all drivers of keloid recurrence. Depending on the lesion and patient, management may require integration with specialist options such as intralesional therapy, pressure therapy, silicone-based care, or carefully selected surgical approaches.

The recurrence-prevention plan should be established before treatment begins, especially for large or previously recurrent keloids.

How to Apply This to Your Project

The recommended parameters should be applied within a clinician-supervised, device-specific protocol:

If your primary focus is initial parameter selection: Begin within the 35–50 W continuous-wave or chopped-mode framework, using lower power for more erythematous lesions and adjusting only from observed tissue response.
If your primary focus is epidermal protection: Maintain continuous surface cooling with a clear, air-free cooling medium compatible with the laser system throughout energy delivery.
If your primary focus is treatment safety: Keep the handpiece moving, avoid excessive overlap and pulse stacking, and stop short of blanching, coagulation points, charring, or other signs of overt thermal injury.
If your primary focus is defining the endpoint: Use delayed or prolonged reperfusion time as the principal endpoint rather than vessel rupture, purpura, whitening, or visible tissue destruction.
If your primary focus is long-term control: Plan approximately 3–5 treatments 6–8 weeks apart and pair laser therapy with an individualized strategy for reducing recurrence.

Large keloids should be treated as deep, vascular, thermally sensitive lesions: controlled hypoperfusion and gradual remodeling are the goals, while visible tissue destruction signals excessive treatment.

Summary Table:

Parameter/Technique	Recommendation
Power	35-50 W (lower for erythematous)
Mode	Continuous-wave or chopped
Cooling	Continuous ice or cooling device
Endpoint	Prolonged reperfusion time, no blanching
Sessions	3-5 at 6-8 week intervals
Combination	Plan recurrence prevention, consider CO2 cautiously

Ensure safe and effective laser treatments with BELIS's advanced 1064 nm Nd:YAG lasers, designed for dermatologists and clinics. Our equipment meets high standards and can enhance patient outcomes. Contact our specialists today to learn how BELIS can support your practice with reliable, professional-grade aesthetic technology.